Arrow Fat Left Icon Arrow Fat Right Icon Arrow Right Icon Cart Icon Close Circle Icon Expand Arrows Icon Facebook Icon Twitter Icon Youtube Icon Hamburger Icon Information Icon Down Arrow Icon Mail Icon Mini Cart Icon Person Icon Ruler Icon Search Icon Shirt Icon Triangle Icon Bag Icon Play Video
We've Moved! Coding Leader is now Healthcare Training Leader. Visit us at www.HCTrainingLeader.com We've Moved! Coding Leader is now Healthcare Training Leader. Visit us at www.HCTrainingLeader.com

Three New HCPCS Codes

The Centers for Medicare & Medicaid Services (CMS) requests Medicare Administrative Contractors (MACs) utilize three new HCPCS codes in the HCPCS file: Q5103 Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg; Q5104 Injection, infliximab-abda, biosimilar, (renflexis), 10 mg; and Q2041 Axicabtagene Ciloleucel, up to 200 million autologous Anti-CD19 CAR T Cells, Including leukapheresis and dose preparation procedures, per infusion, according to provided CMS instructions.

Full Transmittal: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2018Downloads/R3997CP.pdf

Subject: Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes -April 2018 Update

Number: 3997

Title: 10454

Release Date: March 7, 2018

Effective Date: April 1, 2018

Implementation Date: April 2, 2018

Special Notes: Transmittal 3966, dated February 2, 2018, is being rescinded and replaced by Transmittal 3997, dated, March 7, 2018, Year to add business requirement 10454.7. All other information remains the same.

  • Post author
    Lacy Gaskins